The Study to Accelerate Information of Molecular Signatures (AIMS) found RA patients whose treatment was guided by the PrismRA blood test had three times better clinical responses compared to patients that didn’t.
The Study to Accelerate Information of Molecular Signatures (AIMS) found RA patients whose treatment was guided by the PrismRA blood test had three times better clinical responses compared to patients that didn’t.
Copyright © 2024 | WordPress Theme by MH Themes
